NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT

NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Secures FDA Clearance for Innovative Arrhythmia Assessment Device

HeartBeam (NASDAQ: BEAT) has received FDA 510(k) clearance for its groundbreaking HeartBeam system, a credit card-sized, cable-free ECG device designed for comprehensive arrhythmia assessment. The system enables patients to record high-fidelity heart signals from three directions during symptoms, with data transmitted to physicians for timely review and action. This milestone marks the first FDA-cleared device of its kind and lays the foundation for future advancements, including synthesized 12-lead ECGs, AI-driven arrhythmia detection, and heart attack risk assessment. HeartBeam aims to transform cardiac care by delivering actionable insights and predictive diagnostics for patients and physicians globally.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer